Merck says EU CHMP backs Keytruda-Padcev perioperative use in muscle-invasive bladder cancer
MRK•Phase 3 KEYNOTE-B15 results cited
The recommendation follows the Phase 3 KEYNOTE-B15 study, which showed an event-free survival hazard ratio of 0.53 and an overall survival hazard ratio of 0.65 versus chemotherapy.
EU CHMP backs perioperative Keytruda-Padcev use
Merck says the EU Committee for Medicinal Products for Human Use (CHMP) backed Keytruda with Padcev for perioperative use in resectable muscle-invasive bladder cancer. A European Commission decision is due in Q4 2026.
